Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eravacycline for sepsis due to carbapenem-resistant gram-negative bacteria (observational cohort)
ChiCTR2600122900Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Apr 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of eravacycline in sepsis and septic shock, sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: 14-day clinical efficacy rate. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
eravacycline
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on ChiCTR2600122900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122900.